Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha

References

• Mageed R. A., Prud'homme G. J. Immunopathology and the gene therapy of lupus. Gene Ther 2003; 10: 861–4
   PubMed Web of Science ®Google Scholar
• Cornall R. J., Cyster J. G., Hibbs M. L., Dunn A. R., Otipoby K. L., Clark E. A., et al. Polygenic autoimmune traits: Lyn, CD22, and SHP‐1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998; 8: 497–508
   PubMed Web of Science ®Google Scholar
• Pan C., Baumgarth N., Parnes J. R. CD72‐deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999; 11: 495–506
   PubMed Web of Science ®Google Scholar
• Pritchard N. R., Cutler A. J., Uribe S., Chadban S. J., Morley B. J., Smith K. G. Autoimmune‐prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr Biol 2000; 10: 227–30
   PubMed Web of Science ®Google Scholar
• Watanabe‐Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314–17
   PubMed Web of Science ®Google Scholar
• Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda T., et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–76
   PubMed Web of Science ®Google Scholar
• Mandik‐Nayak L., Seo S., Sokol C., Potts K., Bui A., Erikson J. MRL‐lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti‐double‐stranded DNA B cells. J Exp Med 1999; 189: 1799–814
   PubMedGoogle Scholar
• McDonnell T. J., Deane N., Platt F. M., Nunez G., Jaeger U., McKearn J. P., et al. Bcl‐2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 58: 79–88
   Google Scholar
• Potter P. K., Cortes‐Hernandez J., Quartier P., Botto M., Walport M. J. Lupus‐prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol 2003; 170: 3223–32
   PubMed Web of Science ®Google Scholar
• Licht R., Dieker J. W., Jacobs C. W., Tax W. J., Berden J. H. Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 2004; 22: 139–45
   PubMed Web of Science ®Google Scholar
• Mysler E., Bini P., Drappa J., Ramos P., Friedman S. M., Krammer P. H., et al. The apoptosis‐1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994; 93: 1029–34
   PubMed Web of Science ®Google Scholar
• Grondal G., Traustadottir K. H., Kristjansdottir H., Lundberg I., Klareskog L., Erlendsson K., et al. Increased T‐lymphocyte apoptosis/necrosis and IL‐10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus 2002; 11: 435–42
   PubMed Web of Science ®Google Scholar
• Gaipl U. S., Munoz L. E., Grossmayer G., Lauber K., Franz S., Sarter K., et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007; 28: 114–21
   PubMed Web of Science ®Google Scholar
• Baumann I., Kolowos W., Voll R. E., Manger B., Gaipl U., Neuhuber W. L., et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 191–201
   PubMed Web of Science ®Google Scholar
• Munoz L. E., van Bavel C., Franz S., Berden J., Hermann M., van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008; 17: 371–5
   PubMed Web of Science ®Google Scholar
• Lenardo M., Chan K. M., Hornung F., McFarland H., Siegel R., Wang J., et al. Mature T lymphocyte apoptosis‐immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999; 17: 221–53
   PubMed Web of Science ®Google Scholar
• Mevorach D., Zhou J. L., Song X., Elkon K. B. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188: 387–92
   PubMed Web of Science ®Google Scholar
• Georgescu L., Vakkalanka R. K., Elkon K. B., Crow M. K. Interleukin‐10 promotes activation‐induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 1997; 100: 2622–33
   PubMed Web of Science ®Google Scholar
• Sytwu H. K., Liblau R. S., McDevitt H. O. The roles of Fas/APO‐1 (CD95) and TNF in antigen‐induced programmed cell death in T cell receptor transgenic mice. Immunity 1996; 5: 17–30
   PubMed Web of Science ®Google Scholar
• Enghard P., Langnickel D., Riemekasten G. T cell cytokine imbalance towards production of IFN‐gamma and IL‐10 in NZB/W F1 lupus‐prone mice is associated with autoantibody levels and nephritis. Scand J Rheumatol 2006; 35: 209–16
   PubMed Web of Science ®Google Scholar
• Jacob C. O., McDevitt H. O. Tumour necrosis factor‐α in murine autoimmune ‘lupus’ nephritis. Nature 1988; 331: 356–8
   PubMed Web of Science ®Google Scholar
• Lee S. H., Park S. H., Min J. K., Kim S. I., Yoo W. H., Hong Y. S., et al. Decreased tumour necrosis factor‐beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 1997; 6: 603–9
   PubMedGoogle Scholar
• Schotte H., Willeke P., Tidow N., Domschke W., Assmann G., Gaubitz M., et al. Extended haplotype analysis reveals an association of TNF polymorphisms with susceptibility to systemic lupus erythematosus beyond HLA‐DR3. Scand J Rheumatol 2005; 34: 114–21
   PubMed Web of Science ®Google Scholar
• Lu L. Y., Keng H. M., Chu J. J., Lin X. T., Hsu C. M., Sung P. K. TNF receptor I polymorphism is associated with persistent palindromic rheumatism. Scand J Rheumatol 2007; 36: 278–84
   PubMed Web of Science ®Google Scholar
• Gabay C., Cakir N., Moral F., Roux‐Lombard P., Meyer O., Dayer J. M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303–8
   PubMed Web of Science ®Google Scholar
• Charles P., Smeenk R., De Jong J., Feldmann M., Maini R. N. Assessment of antibodies to double‐stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open‐label and randomized placebo‐controlled trials. Arthritis Rheum 2000; 43: 2383–90
   PubMed Web of Science ®Google Scholar
• Ferraro‐Peyret C., Coury F., Tebib J. G., Bienvenu J., Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis‐induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two‐year prospective study. Arthritis Res Ther 2004; 6: R535–43
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R. F., Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007; 36: 418–23
   PubMed Web of Science ®Google Scholar
• O'Shea J. J., Ma A., Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 37–45
   PubMed Web of Science ®Google Scholar
• Tucek‐Szabo C. L., Andjelic S., Lacy E., Elkon K. B., Nikolic‐Zugic J. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation‐induced death can occur without Fas receptor. J Immunol 1996; 156: 192–200
   PubMedGoogle Scholar
• Kollias G., Douni E., Kassiotis G., Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175–94
   PubMed Web of Science ®Google Scholar
• Hay E. M., Bacon P. A., Gordon C., Isenberg D. A., Maddison P., Snaith M. L., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–58
   PubMedGoogle Scholar
• Jury E. C., Kabouridis P. S., Abba A., Mageed R. A., Isenberg D. A. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1343–54
   PubMed Web of Science ®Google Scholar
• Herndon F. J., Hsu H. C., Mountz J. D. Increased apoptosis of CD45RO‐ T cells with aging. Mech Ageing Dev 1997; 94: 123–34
   PubMedGoogle Scholar
• Hermann M., Voll R. E., Zoller O. M., Hagenhofer M., Ponner B. B., Kalden J. R. Impaired phagocytosis of apoptotic cell material by monocytes‐derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1242–50
   Google Scholar
• Gordon C., Matthews N., Schlesinger B. C., Akbar A. N., Bacon P. A., Emery P., et al. Active systemic lupus erythematosus is associated with the recruitment of naive/resting T cells. Br J Rheumatol 1996; 35: 226–30
   PubMedGoogle Scholar
• Fritsch R. D., Shen X., Illei G. G., Yarboro C. H., Prussin C., Hathcock K. S. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2184–97
   PubMedGoogle Scholar
• Aggarwal S., Gallapudi S., Gupta S. Increased TNF‐α‐induced apoptosis in lymphocytes from aged humans: changes in TNF‐α receptor expression and activation of caspases. J Immunol 1999; 162: 2154–61
   PubMedGoogle Scholar
• Elzey B. D., Griffith T. S., Herndon J. M., Barreiro R., Tschopp J., Ferguson T. A. Regulation of Fas ligand‐induced apoptosis by TNF. J Immunol 2001; 167: 3049–56
   PubMedGoogle Scholar
• Kobayashi T., Okamoto K., Kobata T., Hasunuma T., Sumida T., Nishioka K. Tumour necrosis factor α regulation of the Fas‐mediated apoptosis‐signaling pathway in synovial cells. Arthritis Rheum 1999; 42: 519–26
   PubMedGoogle Scholar
• Orlinick J. R., Elkon K. B., Chao M. V. Separate domains of the human Fas ligand dictates self‐association and receptor binding. J Biol Chem 1997; 272: 32221–9
   PubMedGoogle Scholar
• Magalhães M. B., da Silva L. M., Voltarelli J. C., Donadi E. A., Louzada‐Junior P. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36: 442–7
   PubMed Web of Science ®Google Scholar
• Mamoune A., Saraux A., Delaunay J. L., Le Goff P., Youinou P., Le Corre R. Autoantibodies to CD45 in systemic lupus erythematosus. J Autoimmun 1998; 11: 485–8
   PubMedGoogle Scholar
• Emlen W., Niebur J., Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685–92
   PubMed Web of Science ®Google Scholar
• Wu A., Hua H., Munson S., McDevitt H. O. Tumor necrosis factor‐alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002; 99: 12287–92
   PubMed Web of Science ®Google Scholar
• Ehrenstein M. R., Evans J. G., Singh A., Moore S., Warnes G., Isenberg D. A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti‐TNF therapy. J Exp Med 2004; 200: 277–85
   PubMed Web of Science ®Google Scholar
• Kovacs B., Vassilopoulos D., Vogelgesang S. A., Tsokos G. C. Defective CD3‐mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF‐alpha. Clin Immunol Immunopathol 1996; 81: 293–302
   PubMedGoogle Scholar
• Ashkenazi A., Dixit V. M. Death receptors: signaling and modulation. Science 1998; 281: 1305–8
   PubMed Web of Science ®Google Scholar
• Sundararajan R., Cuconati A., Nelson D., White E. Tumor necrosis factor‐alpha induces Bax‐Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J Biol Chem 2001; 276: 45120–7
   PubMedGoogle Scholar
• Beg A. A., Baltimore D. 1996. An essential role for NF‐κB in preventing TNF‐α‐induced cell death. Science 1996; 274: 782–4
   PubMed Web of Science ®Google Scholar
• Natoli G., Costanzo A., Ianni A., Templeton D. J., Woodgett J. R., Balsano C., et al. Activation of SAPK/JNK by TNF receptor I through a non‐cytotoxic TRAF‐2 dependent pathway. Science 1997; 275: 200–3
   PubMed Web of Science ®Google Scholar
• Yeh W. C., Shahinian A., Speiser D., Kranus J., Billia F., Wakeham A., et al. Early lethality, functional NF‐kB activation and increased sensitivity to TNF‐induced cell death in TRAF‐2 deficient mice. Immunity 1997; 7: 715–25
   PubMed Web of Science ®Google Scholar